Тип публикации: статья из журнала
Год издания: 2009
Идентификатор DOI: 10.1007/s10517-009-0695-8
Ключевые слова: Adenoma of the prostate, Afala, Benign prostatic hyperplasia, immunomodulating agent, unclassified drug, absence of side effects, adult, aged, article, bladder irritation, bladder obstruction, clinical article, controlled study, drug efficacy, drug safety, human, long term care, low drug dose, male, micturition, monotherapy, prostate hypertrophy, residual urine, Aged, 80 and over, Antibodies, Humans, Immunologic Factors, Middle Aged, Prostatic Hyperplasia, Treatment Outcome, Urodynamics
Аннотация: The use of ultralow doses of antibodies to prostate-specific antigen (afala) for long-term treatment of benign prostatic hyperplasia in patients with moderate symptoms rapidly and effectively reduces irritative and obstructive symptoms, significantly decreases residual urine volume, and increases the rate of urination. Afala therapПоказать полностьюy is indicated for patients with stage I-II benign prostatic hyperplasia of moderately pronounced symptoms. © 2009 Springer Science+Business Media, Inc.
Журнал: Bulletin of Experimental Biology and Medicine
Выпуск журнала: Vol. 148, Is. 2
Номера страниц: 308-311